MarketPeel
Insider Trading Intelligence
Pricing
…
DB

Daniel Barber

AQST
PRESIDENT AND CEO · AQUESTIVE THERAPEUTICS, INC. · CIK 0001742266
FILING MIX · LIFETIME62%/38%
BUYS
16
SELLS
10
TOTAL VALUE
$5.88M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
635,574
AVG SELL PX
$4.31
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Daniel Barber, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+40.00%-0.72%-3.14%+2.42%+5.82%—
14d5+20.00%-7.60%-4.23%-3.36%-4.08%—
30d5+20.00%+3.23%-1.01%+4.24%-1.12%—
60d5+40.00%+4.77%+2.42%+2.35%+4.78%—
90d5+80.00%+14.58%+1.20%+13.38%+0.55%—
180d5(1 pending)+100.00%-14.25%-1.28%-12.97%-12.92%—
1y5(3 pending)+100.00%+138.39%+6.13%+132.26%+132.26%—
2y5(3 pending)+100.00%+204.91%+33.98%+170.94%+170.94%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AQST · 635,574 shares · as of Jun 15, 2026
0296,358592,715889,0731,185,430202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 10 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,000$4.16$104.0K635,574Jun 15, 2026Jun 17, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,257$4.29$35.4K660,574May 15, 2026May 18, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
335,922$4.18$1.40M668,831May 5, 2026May 7, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
180,677$4.17$754.0K1,004,753Mar 10, 2026Mar 11, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
523,000$4.29$2.24M523,000Mar 9, 2026Mar 11, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
262,000——1,185,430Mar 9, 2026Mar 11, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
91,343$6.03$551.2K923,430Sep 26, 2025Sep 29, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
400$6.00$2.4K1,014,773Sep 19, 2025Sep 22, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
53,998$2.65$143.1K1,015,173Mar 9, 2025Mar 11, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
293,100——293,100Mar 7, 2025Apr 13, 2026 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
272,000——1,098,478Mar 7, 2025Mar 11, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
408,000——408,000Mar 7, 2025Mar 11, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
29,307$2.65$77.7K1,069,171Mar 7, 2025Mar 11, 2025 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
37,938$4.88$185.1K845,364Mar 9, 2024Mar 12, 2024 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
SALE
President and CEO
56,824$4.88$277.3K826,478Mar 9, 2024Oct 2, 2024 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
363,900——363,900Mar 7, 2024Mar 11, 2024 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
242,600——883,302Mar 7, 2024Mar 11, 2024 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
223,500——223,500Aug 9, 2023Aug 9, 2023 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
223,500——223,500May 5, 2023May 9, 2023 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
447,000——640,702Mar 9, 2023Mar 9, 2023 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Aug 5, 2022Aug 8, 2022 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
91,743$0.96$88.1K193,702Jun 8, 2022Jun 10, 2022 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
91,743$0.13$11.9K91,743Jun 8, 2022Jun 10, 2022 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
225,000——225,000Mar 10, 2022Mar 14, 2022 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Mar 11, 2021Mar 15, 2021 ↗View →
AQST
AQUESTIVE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
110,000——110,000Mar 16, 2020Mar 18, 2020 ↗View →
Other insiders · AQST
Loading peer insiders…
About this filer
CIK 0001742266
ROLE
President and CEO
PRIMARY
AQST
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001742266DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback